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Abstract Previous evidence suggested an anti-oncogenic role 
for lysyl oxidase, mainly in ras-transformed cells. Here we prove 
that recombinant lysyl oxidase is actually able to antagonize 
p21-Ha-Ras-induced Xenopus laevis oocyte maturation. Lysyl 
oxidase was also effective on progesterone-dependent matura-
tion, indicating a block lying downstream of Ras. Maturation 
induced by activated 'maturation promoting factor', normally 
triggered by progesterone, was also inhibited by lysyl oxidase. 
Finally, lysyl oxidase did not abolish p42Erk2 phosphorylation 
upon maturation triggering, suggesting a block downstream of 
Erk2. Further investigation showed that lysyl oxidase action 
depends on protein synthesis and is therefore probably mediated 
by a newly synthesized protein. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Lysyl oxidase (protein 6-oxidase; EC 1.4.3.13) (LOX) [1-3] 
is a copper-dependent enzyme that converts by oxidative de-
amination the peptidyl lysine in tropocollagen and tropoelas-
tin into a-aminoadipic-A-semialdehydes [4-8]. Since this step 
is the necessary precursor to cross-linkage formation, LOX is 
considered the key enzyme in the process of collagen matura-
tion and therefore of extracellular matrix (ECM) stabilization. 
Primary or secondary alterations of LOX expression and/or 
activity have been described in several diseases characterized 
by serious impairment of connective tissues [9-12] or by 
pathological fibrosis [13-15]. LOX is synthesized as a 50 kDa 
pre-pro-enzyme that is translocated to the extracellular com-
partment, where a specific protease releases the active 30 kDa 
holo-enzyme [16,17], although the pro-peptide does not seem 
to be necessary for the extracellular translocation [18]. 
Despite its quite well known physiological activity, the role 
of LOX has recently been reconsidered on the basis of new 
experimental evidence, where the enzyme appears to be in-
volved in the oncogenic reversion process. It has been ob-
served that LOX expression and activity are down-regulated 
in many malignant cell lines derived from human tumors [19], 
as well as in several oncogenic transformed cell models [20-
24]. Surprisingly, in these cellular models, mainly H-Ras 
transformed, LOX expression returned to the normal levels, 
no matter how the reversion of the phenotype occurred, 
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whether after treatment with interferon α/β [20,21], azatyro-
sine [22] or spontaneously [23,24]. LOX involvement in cellu-
lar phenotype control has also been stressed in models of 
cellular differentiation [25]. A recent finding by Harada's 
group [26] has shed new light on the role of LOX in trans-
formed cell reversion. They proved that IRF-1, a well char-
acterized tumor suppressor induced by interferon, is able to 
activate the LOX promoter. This evidence provides a reason-
able explanation for both flat reversion and LOX expression 
induced by interferon cc/ß [20]. Another recent observation 
suggestive of a role of LOX in tumor suppression showed 
that the LOX locus lies within the critical region of loss in 
human myelodysplasia and acute myelogenous leukemia [47]. 
Nevertheless, there are no hypotheses so far on how LOX 
could actually function as a tumor suppressor. Its extracellu-
lar position suggests a possible indirect action through a mod-
ification of the components of the ECM, but an action on 
some unknown intracellular substrate cannot be ruled out 
[21]. In fact, it is known that, at least in vitro, LOX can 
oxidize substrates other than elastin and collagen [27]. 
In the present report we tried to clarify some of the ques-
tions raised above. We took advantage of the Xenopus laevis 
oocyte system. Stage VI X. laevis oocytes turned out to be a 
very useful model to unravel the signal transduction involved 
in mitogenesis and other oncogene-dependent processes 
[28,29]. In particular, this model has been largely utilized to 
study Ras oncogenic effects. Injection of activated p21-Ha-
Ras proteins into X. laevis oocytes triggers their meiotic ma-
turation within 10-12 h, mimicking the physiological proges-
terone effect [30]. Therefore, in this model, induction of ma-
turation has been assimilated as equivalent to induction of 
transformation in the cellular model counterpart [31]. The 
oocyte cell also allows direct micro-injection of the protein 
object of study and carries the complete machinery for any 
needed post-translocation modifications. In our study we 
tested the hypothesis of a direct interference of LOX in the 
Ras-dependent pathway, by co-injecting oncogenic p21-Ha-
Rasva112 and mature LOX proteins into X. laevis oocytes. Fur-
thermore, our approach addressed the issue regarding the 
possibility of an intracellular action of LOX, since in our 
experiments we used isolated oocytes, ruling out the possibil-
ity of an indirect effect through the ECM. 
2. Materials and methods 
2.1. Recombinant proteins 
2.1.1. Lysyl oxidase. LOX and LOX(Acat) fragments were ampli-
fied by reverse transcriptase polymerase chain reaction (RT-PCR) 
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(Boehringer, Mannheim, Germany) from human fibroblast primary 
cell culture. The following primers were used: forward 5'-GGG 
GAT CCG AGC TCG AGA TGC GGT ACC ACC-3' and reverse 
5'-AGA GAA TTC AGA АСА CCA GGC ACT GAT-3' for LOX; 
forward 5'-AAG GAT CCC TAC TAC АТС CAG GCA TCC A c e -
s' and reverse 5'CCG AAT TCG CTT TGT GGC CCT CGG CCA 
CTC-3' for LOX(Acat). The PCR was run in the buffer recommended 
by the manufacturer, only raising the MgCl2 concentration to 2 mM. 
The amplification conditions were: for LOX, 1 min denaturation, 
1 min annealing at 56°C, 2 min elongation at 72°C for 32 cycles; 
for LOX(Acat), 30 s denaturation, 30 s annealing, 1 min elongation 
at 72°C for 28 cycles. The PCR products were respectively 793 and 
444 bp. In particular, LOX encompassed the region 588-1380 of the 
human LOX eds [48], while LOX(Acat) corresponded to the region 
731-1041. Their identities were first checked by restriction mapping 
and finally by chain-termination sequencing [32]. Taking advantage of 
the restriction sites introduced into the PCR primers, BamHl for the 
forward and R-oRI for the reverse primers, the two PCR products 
were cloned into the pTrc(His)A,B,C prokaryotic expression vector 
system (InVitrogen, San Diego, CA, USA). In order to obtain the 
insertion in frame with respect to the vector starting codon ATG, 
LOX was cloned in the type A vector and LOX(Acat) in the В vector. 
The stop codon was included in the PCR fragment for LOX, since we 
amplified the cDNA portion encoding the full mature protein, while 
for the LOX(Acat) fragment, missing the 3' part of the LOX coding 
sequence, it was provided by the expression vector, adding 11 amino 
acids at the COOH terminus. The two recombinants were expressed in 
Escherichia coli JM109 strain upon induction by 2 mM isopropyl-ß-D-
thiogalactopyranoside (IPTG) for 3-5 h. After lysis in 8 M urea, 
100 mM NaH 2P0 4 , 10 mM Tris-HCl, pH 8.0 the proteins were pu-
rified by affinity chromatography using Ni-NTA silica resin in column 
or in batch (Qiagen, Hilden, Germany). The non-specific binding was 
washed out twice by 2 volumes of the same buffer, but at pH 6.3. 
Finally, the recombinant proteins were collected by elution with wash-
ing buffer/0.1 M EDTA and checked for purity on 12% SDS-poly-
acrylamide gel electrophoresis [33]. The purified proteins were then 
dialyzed against 20 mM MES, pH 7.0 or PBS, pH 7.2. The average 
preparation resulted in a 90% pure recombinant protein. Since the two 
proteins are poorly dyed by the Coomassie blue (Bradford) method 
[34], their concentrations were estimated by OD2eo, according to the 
calculated A28o of 1.43 for LOX(Acat) and 1.95 for LOX. 
2.1.2. p21-Ha-RasvaU2. The p21-Ha-Rasva112 recombinant protein 
was engineered and purified as previously described [35]. Briefly, after 
induction by temperature shift to 42°C, the urea extracts (7 M urea, 
20 mM MES, pH 7.0) were further purified through a Sephadex 
G-100 column (90x2.5 cm), using as eluant the same buffer as above. 
The different fractions were analyzed by SDS-PAGE. The ones con-
taining more than 90% pure p21-Ha-Ras were collected and dialyzed 
against 20 mM MES, pH 7.O. The protein concentration was esti-
mated by the Bradford method. 
2.1.3. Tropoelastin. The bacteria transformed with the plasmid 
pAS-tropoelastin were kindly provided by Dr. J. Rosenbloom (School 
of Dental Medicine, University of Pennsylvania, Philadelphia, PA, 
USA). The expression and preparation of the recombinant human 
tropoelastin were performed as described [36,37]. Briefly, an aliquot 
of an overnight culture of bacteria containing the specific expression 
vector was diluted 1:50 in 1 liter of L broth containing 50 μg/ml of 
ampicillin and allowed to grow at 37°C with shaking for about 90 min 
(OD590 = 0.6-0.7). Then the cells were collected and washed three 
times in lysine-free RPMI medium (RMPI 1640, Select-Amine kit, 
Life Technologies, NY) and incubated for 10 min with shaking at 
37°C. Then the specific protein expression was induced by adding 
60 μg/ml of nalidixic acid. After 2 h of further incubation [L-4,5-
3H]lysine (1-2 mCi/1) was added and the incubation was continued 
under the same conditions for 3 more hours. The labeled cells were 
collected and washed in phosphate buffer and resuspended in 50 mM 
Tris-HCl buffer, pH 8.0, containing 2 mM EDTA-Na2, 1 mM dithio-
threitol and 0.1 mM phenylmethylsulfonyl fluoride. The cell suspen-
sion was then digested with 200 μg/ml of lysozyme, in the presence of 
0.05% sodium deoxycholate, at 4°C for 30 min. 
The bacteria were then Dounce-homogenized and the resulting pel-
let was resuspended in 4 ml of 70% formic acid containing 63 mg of 
CNBr and stirred overnight at room temperature, to get rid off all the 
methionine-containing bacterial proteins. The solution was diluted 
with one-half volume of water and incubated uncovered on ice in a 
hood for 4-5 h to allow the excess HCN to escape. Finally the pellet 
was discarded and the supernatant dialysed against 0.1 M acetic acid. 
The purity of recombinant tropoelastin was analyzed by SDS-PAGE 
and its labeling by autoradiography. Since the degree of tropoelastin 
was more than 90% and there were no additional labeled proteins, we 
did not proceed to further HPLC purification as recommended in the 
original method. 
2.2. Lysyl oxidase assay 
The enzymatic assay was performed using recombinant [L-4,5-
3H]lysine labeled tropoelastin (see above) as substrate. The assay 
was run in 1 ml of incubation buffer, 0.1 M Na-borate, pH 8.0, 
0.15 M NaCl and 5-15 μg of recombinant LOX was used as enzyme 
source. For each assay a sample containing 0.1 mM ß-amino-propio-
nitrile (BAPN) was run as blank. The tritiated H 2 0 2 released from the 
reaction was estimated by ultrafiltration in Amicon-10, according to 
Shackleton [38]. An aliquot from the flow-through was counted with a 
ß-counter. The resulting net cpm (cpm sample—cpm relative BAPN 
sample) was then expressed as pmol of tropoelastin converted into 
cross-linked product, according to its specific 3H incorporation 
(cpm^g). 
2.3. Oocyte maturation and micro-injection 
Oocytes were manually excised from X. laevis ovaries and selected 
according to their size and shape, in order to have a homogeneous 
stage VI population. The micro-injection of the indicated substances 
was performed as previously described [39]. In all the experiments the 
oocytes were incubated in Ringer's buffer at a conditioned room tem-
perature of 16-18°C. The maturation was evaluated after 12-18 h by 
the appearance of a white spot on the animal pole of the treated 
oocytes. Where needed, the oocytes were fixed in 16% TCA and split 
open for a visual verification of the nuclear germinal vesicle status. 
2.4. Maturation promoting factor (MPF) oocyte extract 
MPF was prepared as previously described [40,41]. Within 2 h after 
maturation induced by 10 μg/ml of progesterone, the oocytes were 
homogenized in 80 mM ß-glycerophosphate, 20 шМ EGTA, 15 mM 
MgCl2, 20 mM HEPES, pH 7.5, in a ratio of 20 μ1/10 oocytes. The 
extract was centrifuged at 3000 Xg for 10 min and the supernatants 
used for micro-injection were indicated. 
2.5. p42Erk2 Western blot analysis 
The oocytes were lysed in lysis buffer (PBS, pH 7.2, 0.1% SDS, 1% 
Triton X-100, 0.5% deoxycholate, 1 mM sodium vanadate, 10 mM 
sodium pyrophosphate, 10 mM sodium fluoride, 1 mM phenylmethyl-
sulfonyl fluoride, 10 μΜ aprotinin). Approximately 50 μg of protein 
for each sample was separated in PAGE on a 10% polyacrylamide gel 
(Laemmli, 1970) and blotted to a Hybond-Super С nitrocellulose 
membrane (Amersham, UK). The blots were probed with anti-
p42Erk2 polyclonal antibodies (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) and developed using an alkaline phosphatase con-
jugated second antibody. 
3. Results 
3.1. LOX blocks Ras-dependent GVBD: the effect is reverted 
by a LOX inhibitor 
In preliminary experiments we fixed the amounts of p21-
Ha-RasYa112 protein that would give 60-80% GVBD, since a 
sub-saturated state of the pathway would allow a better de-
tection of either stimulation or inhibition of the maturation 
process. In our experiments we used two different recombi-
nants of LOX: one deprived of the Cu2+ binding/catalytic 
domain, LOX(Acat), and the full active holo-enzyme, LOX. 
In Fig. 1A a scheme of the generation of the two recombi-
nants is shown. Briefly, the fragments 731-1041 for LOX 
(Acat) and 588-1380 for LOX were amplified by PCR from 
human lysyl oxidase cDNA. LOX, the holo-enzyme fragment 
corresponded to the mature lysyl oxidase after proteolytic 
cleavage [16]. The primers that we used contained the restric-
tion sites BamHl at the 5' end and EcoRl at 3' to make the 
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Fig. L A : Generation of recombinant lysyl oxidase fragments. The two lysyl oxidase fragments were obtained by PCR amplification 
man flbroblast total RNA. The PCR primers contained at their 5' end the ВатШ and EcoRl restriction sites needed to subclone the 
fragments into the specific pTrc(His)A or В prokaryotic expression vector. More details are specified in Section 2. B: Kinetic analysis 
zymatic activity of recombinant lysyl oxidase. Lineveawer-Burke plot. 10 μg of recombinant LOX was used for the assay, while the 
the recombinant tropoelastin, labeled with [L-4,5-3H]lysine, was used at the indicated concentrations. The enzymatic activity was 
from the release of tritiated H2O2 and converted into pmol of tropoelastin converted per μg of LOX per hour. A ATm = 1.45 μΜ 
from the equation, i/V=Km/Vmaii l/S+UVmax, describes the linear interpolation of the experimental results. Further details about the 
described in Section 2. 
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resulting PCR products compatible with a directional cloning 
into the prokaryotic expression vector pTrc(His)A,B,C. More 
details are given in Section 2. In Fig. IB a typical enzyme 
kinetic of the recombinant LOX is shown. The apparent 
Km, 1.45 μΜ, calculated from the Lineweaver-Burk plot, is 
consistent with the previously published analysis performed 
on the purified LOX [6,27,36]. When LOX was co-injected 
with p21-Ha-Rasva112, the GVBD was strongly inhibited in a 
dose-dependent fashion, which already accounts for a specific 
action (Fig. 2). The inhibition was quite complete for p21/ 
LOX< 1. On the other hand, LOX alone did not affect the 
quiescent status of the oocyte, while LOX(Acat) only slightly 
affected p21-Ha-Rasva112 -induced oocyte maturation, as 
shown in Table la. Surprisingly, instead, we noticed that 
LOX(Acat) interfered significantly with LOX effects. Further-
more, we tested if LOX effects were affected by BAPN, a 
recognized highly specific LOX inhibitor [42,43]. In Fig. 3 
we show that while BAPN did not affect Ras-dependent 
GVBD, it completely abolished LOX effects. BAPN was ef-
fective both by micro-injection and by addition to the oocyte 
incubation medium, being able to diffuse through the cellular 
membrane (data not shown). These results provide further 
confirmation of the specificity of LOX inhibition of Ras-de-
pendent GVBD. 
3.2. LOX inhibits GVBD triggered by Ras-independent 
pathways 
The above findings did not assess a LOX action specific for 
Ras-dependent meiotic maturation. Thus, the inhibition could 
involve some step common to different GVBD triggering 
pathways. To address this issue we studied LOX effects on 
progesterone-dependent GVBD, which follows a pathway dif-
ferent from that triggered by Ras [29]. As expected, in our 
experimental system, progesterone was able to induce close to 
100% oocyte maturation at concentrations ranging between 
2 and 10 μg/ml (data not shown). As in the Ras-dependent 
process, LOX was able to inhibit progesterone action in a 
dose-dependent way (Fig. 4). Furthermore, Fig. 4 shows 
that, as in Ras experiments, the LOX effect was specific, since 
it was reversed by co-injection of BAPN. In Table lb we also 
show that LOX(Acat) is not able to reproduce LOX effects, 
ruling out any non-specific effect. However, in our experimen-
tal conditions we could not obtain more than 60-70% inhi-
bition of progesterone-induced GVBD, even with concentra-
tions of LOX much higher than those used for p21-Ha-ras 
-
-
-
/ L 
1 
T 
- 0 ^ 
Т / ^ 
^ r ± . 
* 
ft 
t 
>o 0 
1 
100 
so 
411 
211 
9 
- T 
1 
, , 
-
p2l Кач LOX 
L()X/p21 
Fig. 2. Dose-dependent inhibition of p21-Ha-Rasva112 (p21)-induced 
GVBD by recombinant LOX. Different molar ratios of p21 and 
LOX recombinant proteins were injected into X. laevis stage VI 
oocytes. The GVBD was evaluated by the appearance of depigmen-
tation in the animal pole of the oocytes or by physical examination 
of the disappearance of the germinal vesicle, upon dissection of the 
oocytes after TCA fixation. In the insert is shown the relative per-
cent GVBD induced by 0.5 pmol of p21-Ras or 0.3 pmol of re-
combinant LOX alone. The details are specified in Section 2. Each 
point represents the average of at least three independent experi-
ments ± S.E.M. 
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Fig. 3. Reversion of LOX inhibition of GVBD by BAPN. About 
0.3 pmol of recombinant p21-Ha-Rasva112 was injected alone or with 
equimolar amounts of LOX or LOX+BAPN as indicated. Where 
present, 5 nl of 5 mM BAPN solution, in order to have an intra-
oocyte concentration of ~0.01 mM, assuming an average oocyte 
volume of 500 nl. The figure shows the average results of at least 
two independent experiments ± S.E.M. 
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Fig. 4. LOX inhibition of progesterone-dependent GVBD. X. laevis 
oocyte maturation was monitored after 12-18 h in the presence of 
the indicated substances. When present, progesterone was used at a 
concentration of 10 μg/ml. More details are given in Section 2. The 
figure shows the average results of at least three independent experi-
ments ± S.E.M. 
experiments. Unfortunately we were not able to micro-inject 
higher doses of recombinant LOX, because of its instability at 
concentrations above 0.6-0.8 mg/ml. So it remains unclear if 
the incomplete inhibition of the progesterone-dependent 
GVBD process is indicative of a partial or a 'side effect' of 
LOX, as compared with the more radical effects observed on 
the Ras-dependent process. This point will be the object of 
more extended speculation in Section 4. In order to define the 
step inhibited by LOX, we turned our attention to the MPF, 
which is a complex constituted by p34cdc2 and cyclin В [44]. 
This complex is activated upon progesterone treatment 
[41,45]. In Fig. 5 we show that the micro-injection of activated 
MPF from freshly progesterone matured oocytes [40] was able 
to antagonize LOX effects on Ras-dependent GVBD. On the 
other hand, LOX still blocked oocyte maturation when the 
process was triggered by the same MPF preparation alone. All 
together these data suggest a block lying downstream of 
MPF. Going further down the maturation pathway we tested 
the influence of LOX on the activation status of p42Erk2 upon 
Ras or progesterone triggering. The anti-p42Erk2 Western blot 
shown in Fig. 6 demonstrates that LOX micro-injection in 
both cases did not affect the activation. The retardation shift 
due to the p42Erk2 phosphorylation is indeed maintained in 
the presence of LOX. These findings are compatible with a 
Table 1 
Influence of LOX(Acat) fragment on LOX inhibition of Ras or pro-
gesterone-dependent GVBD 
Addition % GVBD 
p21-ras 
+LOX 
+LOX(Acat) 
+LOX+LOX(Acat) 
b 
Progesterone 
+LOX 
+LOX(Acat) 
+LOX+LOX(Acat) 
72 ±10 
3±0.6 
60±6 
32±9 
93 ±5 
52 ±7 
88 ±6 
65 ±7 
GVBD was induced by (a) sub-saturating amounts of p21-Ha-Rasva112 
(0.3 pmol) or (b) 10 μg/ml of progesterone. Where indicated, equimo-
lar amounts of LOX(Acat) or/and LOX were co-injected. The table 
shows the average results of at least three independent experiments 
± S.E.M. 
LOX-dependent block downstream of Erk2. Considering that 
the Ras and progesterone pathways are known to merge at 
Erk2 level, our results provide a rationale for the LOX inhib-
itory effect on both triggering factors. 
3.3. LOX effects are mediated by protein synthesis 
It is known that Ras induction of oocyte maturation is 
independent of protein synthesis [46], while progesterone 
needs newly synthesized protein to achieve its effect [41]. In 
our model we show that LOX also needed active protein syn-
thesis to inhibit the GVBD process. In fact, as shown in Table 
2, cycloheximide was able to relieve completely LOX inhibi-
tion in Ras-induced GVBD. This finding proves that LOX 
acts indirectly, inducing a protein factor(s), which would be 
actually responsible for the above described effects. 
4. Discussion 
Our study shows that mature 30 kDa lysyl oxidase protein 
is actually able to antagonize oncogenic Ras-dependent mei-
otic maturation of X. laevis oocytes. This finding assumes 
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Fig. 5. Reciprocal effects of MPF and LOX in GVBD induction. 
GVBD was induced by 0.3-0.5 pmol of p21-Ha-Rasva112 or by the 
indicated amounts of MPF extract, alone or in the presence of 
0.35 pmol of LOX. Percent GVBD was assessed as specified in 
Table 1 and in Section 2. The figure shows the average results of at 
least three independent experiments ± S.E.M. 
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Fig. 6. Anti-p42Erk2 and anti-phosphotyrosine Western blots of 
oocyte extracts treated with progesterone alone or progesterone plus 
LOX. The oocytes were incubated with Ringer buffer (control), pro-
gesterone 10 μg/ml or micro-injected with 0.3 pmol of p21-Ha-
Ras™112 and/or with 0.35 pmol of LOX where indicated. After the 
usual incubation time needed to observe the induced GVBD (8-
12 h), the oocytes were lysed in lysis buffer and processed for 12% 
PAGE/Western blotting as described in Section 2. The blots were 
developed using alkaline phosphatase-coupled color forming reac-
tion. 
particular interest considering that a role has been claimed for 
LOX in tumor suppression [19-24,26]. Our results show that 
LOX abolished Ras-dependent GVBD in a dose-dependent 
way (Fig. 2). Its effect is specific as we demonstrated that 
co-treatment with BAPN, a strong inhibitor of LOX catalytic 
activity, was able to abolish it (Fig. 3). Furthermore, micro-
injection of a LOX fragment deprived of catalytic activity, 
LOX(Acat), failed to inhibit Ras-dependent GVBD (Table 
1). This also proved that the observed results could not be 
explained by any interference of (His)6 tag at the NH2 termi-
nus of recombinant LOX. We also noticed a partial relief of 
LOX inhibition when LOX(Acat) and LOX were co-injected 
with p21-Ha-Rasva112. This can be explained by a competition 
between the two protein constructs for a common ligand (or 
substrate). Thus, the consequent subtraction of the physiolog-
ical ligand by LOX(Acat), unable to process it, would result in 
the observed impairment of active LOX action. Obviously, 
other models can be compatible with this finding, although 
it does not change the fact that the observed inhibition of Ras 
effects is strictly dependent on the presence of a catalytically 
active LOX. 
The inhibition of GVBD by LOX was effective also when 
triggered by other factors, like progesterone or MPF, a com-
ponent in the kinase cascade leading to oocyte maturation 
(Figs. 4 and 5). It is worth noting the paradoxical results we 
obtained in the experiment with activated MPF. When p21-
Ha-Ras was the trigger of GVBD, co-injection of MPF an-
tagonized the LOX inhibiting effect, while when the MPF 
triggered GVBD, LOX was still able to achieve its inhibition. 
The two apparently contrasting results can be reconciled, if we 
assume that LOX blocks a factor downstream of MPF. In this 
Table 2 
Cycloheximide effects on LOX inhibition of GVBD 
Addition % GVBD 
p21-Ha-Ras 80 ±10 
+CHX 80 ±5 
+LOX 2 ±0.3 
+CHX+LOX 56 ±7 
GVBD was induced by micro-injection of 0.3-0.5 pmol of p21-Ha-
Rasva112 with or without equimolar amounts of LOX. Where indi-
cated, the X. laevis oocytes were treated with 2 μΜ cycloheximide 
(CHX). GVBD evaluation was performed as described in Section 2. 
The table shows the average results of two independent experi-
ments ± S.E.M. 
case, when p21-Ha-Ras has already activated the maturing 
pathway, the addition of MPF does not improve the final 
effect, but it does increase the amount of that putative factor 
in its activated state. As a result, being in constant amount 
during the experiment, LOX might have been unable to con-
trast the excess of target. In the condition when MPF alone 
triggers GVBD, the amount of activated factor/LOX could 
fall in a stoichiometric ratio to allow the observed inhibition. 
In effect MPF induced a percent GVBD similar to or lower 
than that achieved with p21-Ha-Ras, which would corre-
spond, in the above model, to a comparable if not lesser 
amount of activated LOX target. Since it is known that the 
Ras and progesterone maturing pathways merge at the Erk2 
level, we investigated a possible influence of LOX on p42Erk2 
activation. Western blot analysis (Fig. 6) clearly showed that 
LOX-treated oocytes still undergo p42Erk2 phosphorylation 
upon progesterone triggering. Together our data definitely 
account for a LOX-dependent block downstream of Ras 
and closer to the late events preceding the maturation. The 
inhibited step appears to be downstream of MPF, where prob-
ably Ras, progesterone and other maturing signals merge into 
the final common effect. Although so far no difference of Ras 
and progesterone-dependent maturing signals downstream of 
MAP kinases has been proposed, the observed LOX partial 
inhibition (30-60%) of progesterone/MPF-dependent oocyte 
maturation might mean that there are some. Also LOX might 
affect some main meiotic mechanism that mainly inhibits the 
Ras pathway, but at the same time activates negative feed-
backs to block co-targeting signals, like the progesterone-trig-
gered ones. Nevertheless a much simpler explanation, as al-
ready previously mentioned, is that we could not achieve a 
more effective concentration of recombinant LOX for intrinsic 
solubility reasons. In support to this hypothesis the experi-
ment in Fig. 4 showed that the inhibition of LOX of proges-
terone-triggered maturation is dose-responsive in the tested 
range of concentrations. Furthermore, we proved that LOX 
effects toward Ras-induced GVBD are abolished in the pres-
ence of cycloheximide (CHX), an inhibitor of protein synthe-
sis. This strongly suggests that LOX-dependent inhibition is 
mediated by a protein produced during the duration of the 
experiment. Thus, LOX must activate some specific transcrip-
tion factor, driving the production of a protein, actually re-
sponsible for GVBD inhibition. In agreement with the pre-
vious results, this putative factor should block the maturation 
pathway at a point that lies downstream of Ras and MPF and 
Erk2. 
Finally, our study brings new evidence on a possible LOX 
tumor suppressor role. We showed that, although such an 
activity might not directly affect a Ras-dependent biochemical 
step, LOX effects result in an inhibition of a Ras-triggered 
process. Furthermore, our data suggest that LOX effects are 
mediated by a de novo synthesized protein, that blocks the 
oocyte at a late step of its maturation pathway. Although we 
identified a 50 kDa endogenous LOX form in X. laevis 
oocytes, using antibodies raised against our recombinant 
LOX (data not shown), we have no proof that this mechanism 
is actually effective in oocyte maturation. Nevertheless our 
model suggests a possible explanation for LOX inhibition of 
other Ras-induced effects, like mitogenesis and transformation 
in cellular models. 
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